Sponsoring Organization: American Academy of NeurologyTarget Population: Neurologists, patients, other clinicians seeing patients with multiple sclerosis (MS)
Background and Objective
Numerous disabling and painful symptoms of multiple sclerosis are inadequately addressed by our medication arsenal. Many patients with MS seek alternate therapies to help improve their quality of life.
Key Points
A panel of MS experts reviewed the evidence on 29 alternative approaches. They found the evidence sufficient to comment on only 7 of them and derived the following statements:
Cannabinoids: Although tetrahydrocannabinols do not improve objective measures of spasticity, tremor, or bladder incontinence (Level B), they may reduce the symptoms of muscle stiffn…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)